- Assembly Biosciences Inc Extraordinary Shareholders Meeting TranscriptJan 31, 2024
- Assembly Biosciences Inc Partnership with Gilead Sciences Inc to Develop Next-Generation Antiviral Therapeutics Call TranscriptOct 17, 2023
- Assembly Biosciences Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Assembly Biosciences Inc Annual Shareholders Meeting TranscriptMay 25, 2023
- Assembly Biosciences Inc HSV-2 and Transplant-Associated Herpesviruses Research - Corporate Call TranscriptAug 31, 2022
- Assembly Biosciences Inc IFNAR (Interferon-a Receptor Agonist) Research - Corporate Call TranscriptJul 26, 2022
- Assembly Biosciences Inc HBV/HDV Entry Inhibitor Research - Corporate Call TranscriptMar 31, 2022
- Assembly Biosciences Inc Annual Shareholders Meeting TranscriptMay 20, 2021
- Assembly Biosciences Inc Earnings Call TranscriptFeb 25, 2021$66.36 (-1.95%)Earnings
- Assembly Biosciences, Inc. - Special Call TranscriptNov 05, 2020
- Assembly Biosciences, Inc. - Special Call TranscriptJul 20, 2020
- Assembly Biosciences Inc Annual Shareholders Meeting TranscriptJun 11, 2020
- Assembly Biosciences Inc to Discuss HBV Portfolio Progress Call TranscriptMay 07, 2020
- Assembly Biosciences, Inc. - Special Call TranscriptNov 11, 2019
- Assembly Biosciences, Inc Data Highlighting Next-Generation HBV Core Protein Inhibitors at EASL 2019 Call TranscriptApr 15, 2019
Assembly Biosciences Inc IFNAR (Interferon-a Receptor Agonist) Research - Corporate Call Transcript
Welcome, everyone, and good day. I'm John McHutchison, CEO and President of Assembly Bio, and I'd like to welcome you all to our event today. I'm excited about these research webcast we've been hosting for 2 important reasons. First, I'm thrilled that we are showcasing the outstanding work that Bill Delaney and his talented team of sciences have been doing to capitalize novel programs to combat chronic hepatitis B infection and other viral diseases. And secondly, it's allowed us to invite scientific advisers and clinical experts and collaborators like Professor Ed Gane, who joins us today from New Zealand, to give his expert opinion and view on the tremendous unmet need in diseases like hepatitis B and delta infection and the opportunities for new approaches to make a marked difference for our patients.
Before we turn to the content of today's event, I'd like to quickly touch on a few housekeeping items. I'd like to remind you that we'll be making forward-looking statements. So as always, please refer to our SEC
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)